24/7 Market News Snapshot 08 January, 2025 – Vir Biotechnology, Inc. Common Stock (NASDAQ:VIR)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (NASDAQ:VIR) are discussed in this article.
Vir Biotechnology, Inc. (VIR) has experienced a noteworthy surge in its market performance, with shares trading at $11.07, reflecting an extraordinary pre-market increase of over 40% from the previous close of $7.89. This impressive rise indicates a substantial uptick in investor confidence and interest, highlighted by a robust trading volume of 1.62 million shares. Analysts suggest that the momentum surrounding the stock could signify a pivotal moment for the company, warranting close observation as the bullish trend unfolds.

Contributing to this market enthusiasm are promising preliminary results from Vir’s Phase 1 clinical trials for two innovative dual-masked T-cell engagers, VIR-5818 and VIR-5500. VIR-5818 targets HER2-expressing solid tumors and has shown a remarkable safety and efficacy profile among heavily pretreated patients, with 50% of participants experiencing significant tumor reduction. This includes notable anti-tumor activity in advanced HER2-positive colorectal cancer patients, where one individual has maintained a confirmed partial response for over 18 months. Moreover, the treatment demonstrated minimal instances of cytokine release syndrome, reinforcing its favorable safety profile.

On the other hand, VIR-5500 is being explored for metastatic castration-resistant prostate cancer, reporting a 100% rate of prostate-specific antigen responses in participants who received an initial high dose, with more than half achieving significant PSA responses. Its safety profile appears equally robust, with no serious toxicities reported as doses escalated.

Marianne De Backer, CEO of Vir Biotechnology, emphasized the potential of these therapies to address unmet needs in cancer treatment, citing the company’s proprietary PRO-XTEN™ masking technology as a key factor in optimizing patient outcomes. With ongoing trials and further developments anticipated, Vir Biotechnology is poised to make significant advancements in the therapeutic landscape for solid tumors.

Related news for (VIR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.